

4 December 2009

Approval of agreement with Pfizer New Zealand Ltd for clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone (Provera and Depo-Provera)

PHARMAC is pleased to announce the approval of an agreement with Pfizer New Zealand Limited for the supply of clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone (Provera and Depo-Provera).

This was the subject of a consultation letter dated 29 October 2009. In summary, the agreement involves subsidy and price changes for all of the above pharmaceuticals in return for protection from subsidy and/or delisting protection and/or Hospital Supply Status over various periods. Further details of the decision can be found below.

Details of the decision

Clindamycin Injection

- The price and subsidy (ex-manufacturer, excluding GST) for clindamycin injection (Dalacin C) will be reduced in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	New price and subsidy
Clindamycin	Inj phosphate 150 mg per ml, 4 ml	Dalacin C	1	\$19.45	\$16.00

- Dalacin C will have Hospital Supply Status and protection from delisting and subsidy reduction until 30 June 2013.

Cabergoline

- The prices and subsidies (ex-manufacturer, excluding GST) for cabergoline tablets (Dostinex) will be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	New price and subsidy
Cabergoline	Tab 0.5 mg	Dostinex	2	\$26.26	\$16.50
Cabergoline		Dostinex	8	\$105.03	\$66.00

- Dostinex will have protection from delisting and subsidy reduction until 30 June 2012.

Medroxyprogesterone acetate

- The price and subsidy (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Depo-Provera) will be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	New price and subsidy
Medroxyprogesterone acetate	Inj 150 mg per ml, 1 ml, syringe	Depo-Provera	1	\$8.05	\$7.15

- Medroxyprogesterone acetate injection (Depo-Provera) will be listed in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 at the above prices.
- The prices and subsidies (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Provera) will be amended in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	New price and subsidy
Medroxyprogesterone acetate	Tab 2.5 mg	Provera	30	\$2.07	\$3.09
Medroxyprogesterone acetate	Tab 5 mg	Provera	100	\$13.75	\$13.06
Medroxyprogesterone acetate	Tab 10 mg	Provera	30	\$7.57	\$6.85
Medroxyprogesterone acetate	Tab 100 mg	Provera	100	\$104.26	\$96.50
Medroxyprogesterone acetate	Tab 200 mg	Provera	30	\$78.06	\$70.50

- Provera and Depo-Provera will each have Hospital Supply Status and protection from delisting and subsidy reduction until 30 June 2013.

Sulphasalazine

- The prices and subsidies (ex-manufacturer, excluding GST) for sulphasalazine tablets (Salazopyrin and Salazopyrin EN) will be increased in Section B of the Pharmaceutical Schedule from 1 March 2010 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	New price and subsidy
Sulphasalazine	Tab 500 mg	Salazopyrin	100	\$8.42	\$11.68
Sulphasalazine	Tab 500 mg enteric coated	Salazopyrin EN	100	\$9.44	\$12.89

- Salazopyrin and Salazopyrin EN will be listed in Part II of Section H of the Pharmaceutical Schedule from 1 March 2010 at the above prices.
- Salazopyrin and Salazopyrin EN will have protection from delisting and subsidy reduction until 1 July 2013.

Feedback received

We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 12 November 2009 were considered in their entirety in making a decision on the changes. All responses were supportive of the proposal and no issues with the proposal were raised.

More information

If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.